Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study

Phase II RCT found hyperthermic intraperitoneal chemotherapy with carboplatin followed by IV carboplatin-based chemotherapy did not result in improved progression free survival vs IV carboplatin-based chemotherapy alone (n=98; 2.3 vs 15.7 months; HR 1.54; 95% CI, 1.00-2.37).

Journal of Clinical Oncology